While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ:GTHX) appears quite enticing. First and foremost, it levers acumen in the burgeoning small-molecule therapeutics space. Second, G1 Therapeutics stock seems undervalued for what speculators may be getting.Of course, to make the case that GTHX is a bullish idea, an investor must make two critical assumptio ...

Biotechnology stocks can be thrilling and profitable when you’re on the winning side of a trade. G1 Therapeutics’ (NASDAQ:GTHX) started hot, but then the bottom fell out after an unfortunate announcement. With that in mind, G1 Therapeutics stock is just too risky to recommend right now.Based in North Carolina, G1 Therapeutics specializes in oncology (cancer) treatments. To be fair and balanced, I’ll start off with some positive news pertaining to G1 Therapeutics. Then, however, I’ll have to release a bombsh ...

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ...

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ...

- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 - - Management to Host Webcast and Conference Call Today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. ...

- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 - - Management to Host Webcast and Conference Call Today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. ...

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient Population Showed an Approximately Six-Month Improvement in Median OS Among Patients Receiving Trilaciclib in Combination with the ADC Compared to Historical ADC Data - - Prolonged OS Observed in Patients Receiving Trilaci ...

RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will be presented in a poster session during the upcoming 2024 American So ...

RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G ...

RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement (excluding the Asia-Pacific region) for lerociclib for radioprotective uses. Lerociclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Such inhibitors can increase the survival of animals exposed to radiation. Jupit ...